Genomewide association study of tacrolimus concentrations in African American kidney transplant recipients identifies multiple CYP3A5 alleles WS Oetting, DP Schladt, W Guan, MB Miller, RP Remmel, C Dorr, ... American Journal of Transplantation 16 (2), 574-582, 2016 | 127 | 2016 |
Clinical pharmacology considerations for the development of immune checkpoint inhibitors J Sheng, S Srivastava, K Sanghavi, Z Lu, BJ Schmidt, A Bello, M Gupta The Journal of Clinical Pharmacology 57, S26-S42, 2017 | 115 | 2017 |
PharmGKB summary: mycophenolic acid pathway V Lamba, K Sangkuhl, K Sanghavi, A Fish, RB Altman, TE Klein Pharmacogenetics and genomics 24 (1), 73-79, 2014 | 80 | 2014 |
Genotype-guided tacrolimus dosing in African-American kidney transplant recipients K Sanghavi, RC Brundage, MB Miller, DP Schladt, AK Israni, W Guan, ... The pharmacogenomics journal 17 (1), 61-68, 2017 | 73 | 2017 |
Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors LL Siu, H Burris, DT Le, A Hollebecque, N Steeghs, JP Delord, J Hilton, ... Cancer Research 78 (13_Supplement), CT180-CT180, 2018 | 45 | 2018 |
Differentially expressed gene transcripts using RNA sequencing from the blood of immunosuppressed kidney allograft recipients C Dorr, B Wu, W Guan, A Muthusamy, K Sanghavi, DP Schladt, ... PloS one 10 (5), e0125045, 2015 | 31 | 2015 |
Personalized fludarabine dosing to reduce nonrelapse mortality in hematopoietic stem-cell transplant recipients receiving reduced intensity conditioning K Sanghavi, A Wiseman, MN Kirstein, Q Cao, R Brundage, K Jensen, ... Translational Research 175, 103-115. e4, 2016 | 30 | 2016 |
Population pharmacokinetics of ipilimumab in combination with nivolumab in patients with advanced solid tumors K Sanghavi, J Zhang, X Zhao, Y Feng, P Statkevich, J Sheng, A Roy, ... CPT: Pharmacometrics & Systems Pharmacology 9 (1), 29-39, 2020 | 28 | 2020 |
Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors S Lorenzen, LL Siu, H Burris, DT Le, A Hollebecque, N Steeghs, ... | 27 | 2018 |
Population pharmacokinetics of nivolumab in combination with ipilimumab in patients with advanced malignancies J Zhang, K Sanghavi, J Shen, X Zhao, Y Feng, P Statkevich, J Sheng, ... CPT: Pharmacometrics & Systems Pharmacology 8 (12), 962-970, 2019 | 21 | 2019 |
Reporting, visualization, and modeling of immunogenicity data to assess its impact on pharmacokinetics, efficacy, and safety of monoclonal antibodies C Passey, S Suryawanshi, K Sanghavi, M Gupta The AAPS Journal 20, 1-13, 2018 | 12 | 2018 |
Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment A Blaes, D Duprez, T Defor, R Shanley, H Beckwith, T Haddad, D Potter, ... Springerplus 4, 1-7, 2015 | 11 | 2015 |
Gemcitabine and metabolite pharmacokinetics in advanced NSCLC patients after bronchial artery infusion and intravenous infusion AF Alharbi, RA Kratzke, J D’Cunha, MA Maddaus, K Sanghavi, ... Cancer chemotherapy and pharmacology 83, 387-391, 2019 | 7 | 2019 |
BMS-986012, an Anti–fucosyl-GM1 monoclonal antibody as monotherapy or in combination with nivolumab in relapsed/refractory SCLC: results from a first-in-human phase 1/2 study Q Chu, NB Leighl, V Surmont, C van Herpen, A Sibille, B Markman, ... JTO Clinical and Research Reports 3 (11), 100400, 2022 | 6 | 2022 |
Higher fludarabine and cyclophosphamide exposures lead to worse outcomes in reduced-intensity conditioning hematopoietic cell transplantation for adult hematologic malignancy T Takahashi, A Scheibner, Q Cao, R Pearson, K Sanghavi, DJ Weisdorf, ... Transplantation and cellular therapy 27 (9), 773. e1-773. e8, 2021 | 5 | 2021 |
CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab (ħrHuPH20). S Lonardi, I Lugowska, CGCA Jackson, A O'Donnell, R Bahleda, ... Journal of Clinical Oncology 39 (15_suppl), 2575-2575, 2021 | 5 | 2021 |
Population pharmacokinetic and exposure–response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma T Ide, M Osawa, K Sanghavi, HE Vezina Cancer Chemotherapy and Pharmacology 89 (1), 129-140, 2022 | 3 | 2022 |
Nivolumab exposure–response analysis for adjuvant treatment of melanoma supporting a change in posology K Sanghavi, P Vuppala, V Ivaturi, L Hamuro, A Roy, S Suryawanshi CPT: Pharmacometrics & Systems Pharmacology 10 (7), 748-759, 2021 | 3 | 2021 |
Variants associated with tacrolimus troughs in European American kidney transplant recipients: A genome wide association study P Jacobson, M Miller, D Schladt, A Israni, K Sanghavi, C Dorr, R Remmel, ... American Journal of Transplantation 15, 2015 | 3 | 2015 |
Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients T Takahashi, R Pearson, Q Cao, A Scheibner, K Sanghavi, D Weisdorf, ... Cancer chemotherapy and pharmacology 89 (4), 543-549, 2022 | 2 | 2022 |